US 12,303,498 B2
ALK5 inhibitors as skeletal muscle hypertrophy inducers
Pauline Poydenot, Novalaise (FR); Joris Michaud, Lausanne (CH); Mélanie Flaender, Grenoble (FR); Eve Duchemin-Pelletier, Vizille (FR); and Luc Selig, Charenton le Pont (FR)
Assigned to CYTOO, Grenoble (FR)
Appl. No. 16/982,607
Filed by CYTOO, Grenoble (FR)
PCT Filed Mar. 25, 2019, PCT No. PCT/EP2019/057426
§ 371(c)(1), (2) Date Sep. 21, 2020,
PCT Pub. No. WO2019/180269, PCT Pub. Date Sep. 26, 2019.
Claims priority of application No. 18305331 (EP), filed on Mar. 23, 2018.
Prior Publication US 2021/0015807 A1, Jan. 21, 2021
Int. Cl. A61K 31/444 (2006.01); A61K 31/4439 (2006.01); A61K 31/4709 (2006.01); A61K 31/498 (2006.01); A61K 31/519 (2006.01); A61K 31/573 (2006.01); A61K 45/06 (2006.01); A61P 21/00 (2006.01)
CPC A61K 31/444 (2013.01) [A61K 31/4439 (2013.01); A61K 31/4709 (2013.01); A61K 31/498 (2013.01); A61K 31/519 (2013.01); A61K 31/573 (2013.01); A61K 45/06 (2013.01); A61P 21/00 (2018.01)] 5 Claims
OG exemplary drawing
 
1. A method of treating a neuromuscular junction disease, comprising the administration of an ALK5 inhibitor, optionally in combination with a glucocorticoid to a subject in need thereof, wherein the ALK5 inhibitor is not used in combination with an oxytocin receptor agonist, and wherein the ALK5 inhibitor is selected from the group consisting of RepSox and pharmaceutically acceptable salts, hydrates or solvates thereof.